 |
|
U-M researchers ID gene involved in pancreatic cancer
March 03, 2009ANN ARBOR, Mich. - Researchers from the University of Michigan Comprehensive Cancer Center have identified a gene that is overexpressed in 90 percent of pancreatic cancers, the most deadly type of cancer.
Expression of the gene, Ataxia Telangiectasia Group D Complementing gene, called ATDC, is on average 20 times higher in pancreatic cancer cells than in cells from a normal pancreas. What's more, the gene appears to make pancreatic cancer cells resistant to current therapies.
"One of the challenges in pancreatic cancer is that it is biologically aggressive and it does not respond well to chemotherapy or radiation. We found that ATDC not only causes the cancer cells to grow faster and be more aggressive, but it also makes the cancer cells particularly resistant to chemotherapy and radiation. By targeting this gene, we may be able to make cancer cells more sensitive to the therapies we already have in hand," says senior study author Diane Simeone, M.D., director of the Multidisciplinary Pancreatic Cancer Clinic at the U-M Comprehensive Cancer Center.
Results of the study appear in the March issue of Cancer Cell.
The researchers injected into mice tumor cells expressing ATDC and compared that to a separate group of mice injected with tumor cells in which ATDC was suppressed. In the ATDC-expressing group, tumors grew in all the samples and were significantly larger and starting to metastasize, or spread. In the group in which ATDC was not expressed, only minimal signs of tumor growth were seen after 60 days.
"This particular gene promotes the biologic aggressiveness of the cancer," says Simeone, who is also Lazar J. Greenfield Professor of Surgery and Molecular & Integrative Physiology at the U-M Medical School.
In addition, the researchers found that ATDC is most highly expressed at the point when pre-cancerous cells become malignant. ATDC was also linked to increased levels of a signaling protein called beta-catenin, which is known to play a key role in cancer development.
Researchers believe ATDC has potential as a target for developing future therapies. It could also help doctors determine when a patient has pancreatic cancer and when it's chronic pancreatitis, a diagnosis that's often difficult to make without surgery. In some cases, this may allow patients to avoid an operation.
ATDC also appears to be involved in other cancer types, including bladder cancer and lung cancer. Researchers are continuing to investigate its role. This research was done in the laboratory. No tests or therapies related to ATDC are available at this time.
Pancreatic cancer statistics: 37,680 Americans will be diagnosed with pancreatic cancer this year and 34,290 will die from the disease, according to the American Cancer Society
Additional authors: Lidong Wang, David G. Heidt, Cheong J. Lee, Huibin Yang, Eric R. Fearon and Mats Ljungman from U-M; Craig D. Logsdon from M.D. Anderson Cancer Center; and Lizhi Zhang from the Mayo Clinic.
University of Michigan Health System
Pancreatic Cancer Current Events and Pancreatic Cancer News RSSSoft drink consumption may increase risk of pancreatic cancer
Consuming two or more soft drinks per week increased the risk of developing pancreatic cancer by nearly twofold compared to individuals who did not consume soft drinks, according to a report in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Inflammation marker related to obesity is elevated in patients with pancreatic cancer
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center.
Scientists show how molecular switch helps pancreatic cancer beat drugs
Researchers at the Moores Cancer Center at the University of California, San Diego, have found one reason that pancreatic cancer tumors are so difficult to treat with drugs.
Oral COTI-2 is effective in a second animal model of human pancreatic cancer
Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT)announced more positive results today from animal experiments carried out at a prominent Canadian cancer research facility.
Zebrafish journal publishes cancer biology special issue
The zebrafish, a translucent fish often used as a model of human development and disease, offers unique advantages for studying the cause, growth, and spread of tumors using strategies and methods presented in the current "Cancer Biology" special issue of Zebrafish.
Smokeless tobacco called 'moist snuff' is contaminated with harmful substances
A new study on the smokeless tobacco product called moist snuff - placed between lip and gum - has led scientists in Minnesota to urge the tobacco industry to change manufacturing practices to reduce snuff's content of carcinogens.
Combining nanotubes and antibodies for breast cancer 'search and destroy' missions
Single-walled nanotubes-cylinders of carbon about a nanometer in diameter-have been highly touted for potential applications such as ultrastrong fibers, electrical wires in molecular devices, or hydrogen storage components for fuel cells.
Rare pancreatic cancer patients may live longer when treated with radiation therapy
Radiation therapy is effective in achieving local control and palliation in patients with pancreatic neuroendocrine tumors (PNTs), despite such tumors being commonly considered resistant to radiation therapy.
African-Americans with colorectal cancer have poorer outcomes, lower survival rates
New research published in the November issue of the Journal of the American College of Surgeons shows that African-American patients with colorectal cancer are more likely to be diagnosed with advanced disease and are less likely to undergo surgical procedures compared with Caucasians, suggesting that improvements in screening and rates of operation may reduce differences in colorectal cancer outcomes for African-Americans.
Discovery offers potential new pancreatic cancer treatment
Tiny particles that can carry drugs and target cancer cells may offer treatment hope for those suffering with pancreatic cancer. New research to be presented in November at the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting in Los Angeles reveals that tumor-penetrating microparticles (TPM) have been specifically designed to break through hard-to-infiltrate barriers and deliver drugs more effectively and efficiently than the standard form of chemotherapy such as those injected through a vein.
More Pancreatic Cancer Current Events and Pancreatic Cancer News Articles
 |
100 Questions & Answers About Pancreatic Cancer, Second Edition by Eileen O'Reilly (Author), Joanne Frankel Kelvin (Author) Whether you re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor s and patient s view, 100 Questions & Answers About Pancreatic Cancer, Second Edition gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. The authors, a medical oncologist and a nurse with 25 years of experience with cancer patients, provide a comprehensive, step-by-step discussion of what you can expect in the diagnosis and treatment of pancreatic cancer, while patient commentaries provide a real-life understanding of what these steps might mean for your day-to-day life. This book is an invaluable... |
 |
Pancreatic Cancer (M.D. Anderson Solid Tumor Oncology Series) by Andrew M. Lowy (Editor), Steven D. Leach (Editor), Philip Philip (Editor) Since the previous M.D. Anderson Solid Tumor Oncology Series publication on pancreatic cancer, there have been major advances in our understanding of molecular events which underlie pancreatic cancer development, both in the sporadic and inherited forms. We have seen the development of the first mouse models that accurately recapitulate features of the human disease. Several landmark clinical trials in both resectable and metastatic pancreatic cancer have been completed, raising new questions about the standard of care in this disease. Finally, the era of targeted biologic therapies has engendered new excitement about the prospects of more rapid progress in understanding and successfully treating this dreadful disease. Therefore, it is an appropriate time to review these important... |
 |
100 Q&A About Pancreatic Cancer (100 Questions & Answers) by Joanne Frankel Kelvin Eileen O'Reilly (Author) EMPOWER YOURSELF! Whether you’re a newly diagnosed pancreatic cancer patient, a survivor, or a friend or relative of someone with pancreatic cancer, this book offers help. The only text to provide a doctor’s and patient’s view, 100 Questions & Answers About Pancreatic Cancer gives you authoritative, practical answers to your questions about treatment options, post-treatment quality of life, sources of support, and much more. The authors, a medical oncologist and a nurse with 25 years of experience with cancer patients, provide a comprehensive, step-by-step discussion of what you can expect in the diagnosis and treatment of pancreatic cancer, while patient commentaries provide a real-life understanding of what these steps might mean for your day-to-day life. This book is an... |
 |
My Journey With Pancreatic Cancer by Calvin Rains (Author) This book is shared to help all understand the cancer affecting the pancreas which is a vital organ in the digestion of food. Pancreatic cancer is one of the most deadly of cancers affecting the human body. Less than 5% of those diagnosed with Pancreatic Cancer survive the first year.This book is intended to help the patient, their families, and friends to understand the dangers and possible treatments. It is vital that the patient and their families understand the importance of choices of treatment and the possible side effects.This is basically a diary of one patient who has been able to survive five (5) years at this writing. The road can be challenging, but healing is possible if discovered and treated quickly. This book will help the patient and their families to better deal with... |
 |
Pancreatic Cancer: Current and Emerging Trends in Detection and Treatment (Cancer and Modern Science) by Amy Sterling Casil (Author) |
 |
Pancreatic Cancer by Daniel D. Von Hoff (Editor) (Author) Praise for the book “An outstanding text covering all aspects of pancreatic cancer, from embryology through genetics and pathology, and including all avenues of treatment. There are 112 internationally recognized authors, the book is marvelously illustrated, and is a must for all scientists and clinicians interested in neoplasms of the pancreas. It is currently the most up-to-date and complete text on pancreatic cancer available.” -- John L. Cameron, MD The Alfred Blalock Distinguished Service Professor The Johns Hopkins University School of Medicine |
 |
5,001 Reasons to Survive Pancreatic Cancer: A Motivation Book (Volume 1) by Isidro Gomez (Author) This book is intended to motivate and inspire the individual, family, and friends of a pancreatic cancer patient. The words on the following pages are used to trigger the senses and memories of how important this life is and the need to fight through the trials and hardships of a cancer diagnosis. There are 5,001 reasons to survive pancreatic cancer in this book and as you know, this only scratches the surface of reasons to beat the cancer. It is our hope that the following words will conjure up memories of a life filled with meaningful events, trips to wonderful places, and daily routines that bring a smile to your face. As you read these pages, take a moment to think of all the magnificent things you'll do when you beat this cancer. Enjoy life! Enjoy all the things that make up... |
 |
Pancreatic Cancer (Recent Results in Cancer Research) by H. Riess (Editor), A. Goerke (Editor), H. Oettle (Editor) Although pancreatic cancer is one of the most serious forms of cancers, the outlook for patients could be improved. The lack of clinical symptoms of early, surgically removable disease most often limits curative treatment options. The aggressive tumor cell biology, leading to a locally advanced nature of the disease and to early metastases, allows curative resection in only 20% of patients at the time of diagnosis. Patients are therefore often faced with a dreadful prognosis from a state of almost full physical health. Furthermore, because there is a high recurrence rate after curative resection, treatment of this tumor entity becomes a great challenge. This book gives insight into the current understanding of the management of pancreatic cancer and considers recent findings in... |
 |
The Official Patient's Sourcebook on Pancreatic Cancer: A Revised and Updated Directory for the Internet Age by Icon Health Publications (Author) This book has been created for patients who have decided to make education and research an integral part of the treatment process. Although it also gives information useful to doctors, caregivers and other health professionals, it tells patients where and how to look for information covering virtually all topics related to pancreatic cancer (also Cancer pancreas; Pancreatic cancer), from the essentials to the most advanced areas of research. The title of this book includes the word official. This reflects the fact that the sourcebook draws from public, academic, government, and peer-reviewed research. Selected readings from various agencies are reproduced to give you some of the latest official information available to date on pancreatic cancer. Given patients' increasing sophistication... |
 |
The Last Lecture by Randy Pausch (Author), Jeffrey Zaslow (Author) "We cannot change the cards we are dealt, just how we play the hand." --Randy Pausch A lot of professors give talks titled "The Last Lecture." Professors are asked to consider their demise and to ruminate on what matters most to them. And while they speak, audiences can't help but mull the same question: What wisdom would we impart to the world if we knew it was our last chance? If we had to vanish tomorrow, what would we want as our legacy? When Randy Pausch, a computer science professor at Carnegie Mellon, was asked to give such a lecture, he didn't have to imagine it as his last, since he had recently been diagnosed with terminal cancer. But the lecture he gave--"Really Achieving Your Childhood Dreams"--wasn't about dying. It was about the importance of... |
| © 2010 BrightSurf.com |